Physician profile
Mario Roberto Gonzalez
NPI 1396377925
$4,473.71
in general payments reported to CMS, 2019-2025
29 companies · $1,503 in 2025
The $1,503 reported for 2025 was more than what 90% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $623 · 2023: $1,327 · 2024: $579 · 2025: $1,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,409.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $875.46 | 2021-2023 | Krystexxa |
| Amgen INC. | $539.35 | 2023-2025 | Tavneos, Krystexxa, Repatha |
| Janssen Pharmaceuticals, INC | $339.55 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $284.68 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $284.47 | 2023-2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $182.58 | 2022-2025 | Strensiq |
| Boston Scientific Corporation | $149.49 | 2021 | |
| Ascendis Pharma Endocrinology INC | $143.08 | 2025 | Yorvipath |
| Becton, Dickinson and Company | $132.31 | 2025 | Hemosphere |
| Glaxosmithkline, LLC. | $123.78 | 2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $123.25 | 2022 | |
| Jazz Pharmaceuticals INC. | $121.87 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.86 | 2024 | Jardiance |
| Vifor Pharma, INC. | $121.84 | 2022 | |
| Akebia Therapeutics INC | $121.82 | 2025 | Vafseo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $120.27 | 2025 | |
| Novo Nordisk INC | $109.02 | 2025 | Ozempic |
| Calliditas Therapeutics US INC. | $100.00 | 2024 | |
| Phathom Pharmaceuticals, INC. | $100.00 | 2024 | Voquezna |
| Globus Medical, INC. | $86.15 | 2025 | Senza |
| Recordati_rare_diseases_inc. | $76.88 | 2025 | Isturisa |
| Ardelyx, INC. | $55.64 | 2025 | Ibsrela |
| Mannkind Corporation | $37.10 | 2025 | |
| Kyowa Kirin, INC. | $29.01 | 2025 | |
| Axonics, INC. | $27.02 | 2023 | Axonics |
| Soleno Therapeutics, INC. | $22.52 | 2025 | Vykat Xr |
| Abbvie INC. | $19.78 | 2024 | |
| Lilly USA, LLC | $13.52 | 2024 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.